CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1935-1947

  Hu, Kai ^a,b   Luo, Sukun ^a,b   Tong, Lina ^a   Huang, Xin ^a,b   Jin, Wei ^a,b   Huang, Wenjie ^a   Du, Tao ^a,b   Yan, Yan ^a,b   He, Siyi ^a,b   Griffin, George E ^c   Shattock, Robin J ^d   Hu, Qinxue ^a,c  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; CCL28 PROTEIN; CD19 ANTIGEN; CD3E ANTIGEN; CELL ANTIGEN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR7; CYTOKINE; GLYCOPROTEIN GP 140; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NEUTRALIZING ANTIBODY; PLASMID VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHEMOTAXIS; COLON MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOMODULATION; LYMPHOCYTE; MESENTERY LYMPH NODE; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; RECTUM MUCOSA; SPLEEN; SPLEEN CELL; TH1 CELL; TH2 CELL; VAGINA;

AIDS VACCINES; ANIMALS; B-LYMPHOCYTE SUBSETS; CHEMOKINE CCL19; CHEMOKINES, CC; CHEMOTAXIS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HIV ANTIBODIES; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; RECOMBINANT FUSION PROTEINS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; VACCINATION; VACCINES, DNA; VAGINA;

EID: 84881444344     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300120     Document Type: Article

References (81)

1. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
2. Barouch, D. H., and B. Korber. 2010. HIV-1 vaccine development after STEP. Annu. Rev. Med. 61: 153-167.
3. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893.
4. Mascola, J. R., and D. C. Montefiori. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28: 413-444.
5. The rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
6. Gilbert, P. B., M. L. Peterson, D. Follmann, M. G. Hudgens, D. P. Francis, M. Gurwith, W. L. Heyward, D. V. Jobes, V. Popovic, S. G. Self, et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191: 666-677.
7. Robb, M. L. 2008. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372: 1857-1858.
8. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, and K. Choopanya; Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671.
9. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.
10. Hope, T. J. 2011. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat. Med. 17: 1195-1197.
11. Jiang, H., G. Hester, L. Liao, D. C. Montefiori, and M. M. Frank. 2011. Mechanisms by which HIV envelope minimizes immunogenicity. [Published erratum appears in 2011 Immunol. Res. 49: 159.] Immunol. Res. 49: 147-158.
12. Reitter, J. N., R. E. Means, and R. C. Desrosiers. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4: 679-684.
13. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5: 233-236.
14. Kwong, P. D., M. L. Doyle, D. J. Casper, C. Cicala, S. A. Leavitt, S. Majeed, T. D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptorbinding sites. Nature 420: 678-682.
15. Forsell, M. N., W. R. Schief, and R. T. Wyatt. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 4: 380-387.
16. Haynes, B. F., G. Kelsoe, S. C. Harrison, and T. B. Kepler. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30: 423-433.
17. Kwong, P. D., J. R. Mascola, and G. J. Nabel. 2012. The changing face of HIV vaccine research. J. Int. AIDS Soc. 15: 17407.
18. Liu, L., C. Qiu, Y. Huang, J. Xu, and Y. Shao. 2013. Potent T cell responses induced by single DNA vaccine boosted with recombinant vaccinia vaccine. Virol. Sin. 28: 109-115.
19. Kutzler, M. A., and D. B. Weiner. 2008. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9: 776-788.
20. Ferraro, B., M. P. Morrow, N. A. Hutnick, T. H. Shin, C. E. Lucke, and D. B. Weiner. 2011. Clinical applications of DNA vaccines: current progress. Clin. Infect. Dis. 53: 296-302.
21. Bolesta, E., A. Kowalczyk, A. Wierzbicki, C. Eppolito, Y. Kaneko, M. Takiguchi, L. Stamatatos, P. A. Shrikant, and D. Kozbor. 2006. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J. Immunol. 177: 177-191.
22. Boyer, J. D., T. M. Robinson, M. A. Kutzler, R. Parkinson, S. A. Calarota, M. K. Sidhu, K. Muthumani, M. Lewis, G. Pavlakis, B. Felber, and D. Weiner. 2005. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J. Med. Primatol. 34: 262-270.
23. Lillard, J. W., Jr., P. N. Boyaka, D. D. Taub, and J. R. McGhee. 2001. RANTES potentiates antigen-specific mucosal immune responses. J. Immunol. 166: 162-169.
24. Jalah, R., V. Patel, V. Kulkarni, M. Rosati, C. Alicea, B. Ganneru, A. von Gegerfelt, W. S. Huang, Y. J. Guan, K. E. Broderick, et al. 2012. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum. Vaccin. Immunother. 8: 1620-1629.
25. Rodríguez, A. M., M. F. Pascutti, C. Maeto, J. Falivene, M. P. Holgado, G. Turk, and M. M. Gherardi. 2012. IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12-BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS ONE 7: e37801.
26. Kalams, S. A., S. Parker, X. Jin, M. Elizaga, B. Metch, M. Wang, J. Hural, M. Lubeck, J. Eldridge, M. Cardinali, et al; NIAID HIV Vaccine Trials Network. 2012. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS ONE 7: e29231.
27. Litinskiy, M. B., B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3: 822-829.
28. Nardelli, B., O. Belvedere, V. Roschke, P. A. Moore, H. S. Olsen, T. S. Migone, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, and D. M. Hilbert. 2001. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
29. Hahne, M., T. Kataoka, M. Schröter, K. Hofmann, M. Irmler, J. L. Bodmer, P. Schneider, T. Bornand, N. Holler, L. E. French, et al. 1998. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188: 1185-1190.
30. Chorny, A., I. Puga, and A. Cerutti. 2010. Innate signaling networks in mucosal IgA class switching. In Advances in Immunology. F. Sidonia, and C. Andrea, eds. Academic Press, New York, p. 31-69.
31. Hardenberg, G., L. Planelles, C. M. Schwarte, L. van Bostelen, T. Le Huong, M. Hahne, and J. P. Medema. 2007. Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner. Eur. J. Immunol. 37: 2900-2911.
32. Stein, J. V., M. López-Fraga, F. A. Elustondo, C. E. Carvalho-Pinto, D. Rodríguez, R. Gómez-Caro, J. De Jong, C. Martínez-A, J. P. Medema, and M. Hahne. 2002. APRIL modulates B and T cell immunity. J. Clin. Invest. 109: 1587-1598.
33. Planelles, L., C. E. Carvalho-Pinto, G. Hardenberg, S. Smaniotto, W. Savino, R. Gómez-Caro, M. Alvarez-Mon, J. de Jong, E. Eldering, C. Martínez-A, et al. 2004. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 6: 399-408.
34. Rennert, P., P. Schneider, T. G. Cachero, J. Thompson, L. Trabach, S. Hertig, N. Holler, F. Qian, C. Mullen, K. Strauch, et al. 2000. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192: 1677-1684.
35. Ingold, K., A. Zumsteg, A. Tardivel, B. Huard, Q.-G. Steiner, T. G. Cachero, F. Qiang, L. Gorelik, S. L. Kalled, H. Acha-Orbea, et al. 2005. Identification of proteoglycans as the APRIL-specific binding partners. J. Exp. Med. 201: 1375-1383.
36. Hendriks, J., L. Planelles, J. de Jong-Odding, G. Hardenberg, S. T. Pals, M. Hahne, M. Spaargaren, and J. P. Medema. 2005. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 12: 637-648.
37. Nagira, M., T. Imai, K. Hieshima, J. Kusuda, M. Ridanpää, S. Takagi, M. Nishimura, M. Kakizaki, H. Nomiyama, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J. Biol. Chem. 272: 19518-19524.
38. Yanagawa, Y., and K. Onoé. 2002. CCL19 induces rapid dendritic extension of murine dendritic cells. Blood 100: 1948-1956.
39. Hillinger, S., S. C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma. 2003. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J. Immunol. 171: 6457-6465.
40. Toka, F. N., M. Gierynska, and B. T. Rouse. 2003. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J. Virol. 77: 12742-12752.
41. Marsland, B. J., P. Bättig, M. Bauer, C. Ruedl, U. Lässing, R. R. Beerli, K. Dietmeier, L. Ivanova, T. Pfister, L. Vogt, et al. 2005. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22: 493-505.
42. Takamura, K., S. Fukuyama, T. Nagatake, D. Y. Kim, A. Kawamura, H. Kawauchi, and H. Kiyono. 2007. Regulatory role of lymphoid chemokine CCL19 and CCL21 in the control of allergic rhinitis. J. Immunol. 179: 5897-5906.
43. Yasuda, T., T. Kuwabara, H. Nakano, K. Aritomi, T. Onodera, M. Lipp, Y. Takahama, and T. Kakiuchi. 2007. Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells. Blood 109: 449-456.
44. Hillinger, S., S. C. Yang, R. K. Batra, R. M. Strieter, W. Weder, S. M. Dubinett, and S. Sharma. 2006. CCL19 reduces tumour burden in a model of advanced lung cancer. Br. J. Cancer 94: 1029-1034.
45. Westermann, J., T. Nguyen-Hoai, G. Baldenhofer, U. E. Höpken, M. Lipp, B. Dörken, and A. Pezzutto. 2007. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 14: 523-532.
46. Wang, W., H. Soto, E. R. Oldham, M. E. Buchanan, B. Homey, D. Catron, N. Jenkins, N. G. Copeland, D. J. Gilbert, N. Nguyen, et al. 2000. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J. Biol. Chem. 275: 22313-22323.
47. Hieshima, K., H. Ohtani, M. Shibano, D. Izawa, T. Nakayama, Y. Kawasaki, F. Shiba, M. Shiota, F. Katou, T. Saito, and O. Yoshie. 2003. CCL28 has dual roles in mucosal immunity as a chemokine with broad-spectrum antimicrobial activity. J. Immunol. 170: 1452-1461.
48. Lazarus, N. H., E. J. Kunkel, B. Johnston, E. Wilson, K. R. Youngman, and E. C. Butcher. 2003. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J. Immunol. 170: 3799-3805.
49. Hieshima, K., Y. Kawasaki, H. Hanamoto, T. Nakayama, D. Nagakubo, A. Kanamaru, and O. Yoshie. 2004. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J. Immunol. 173: 3668-3675.
50. Feng, N. G., M. C. Jaimes, N. H. Lazarus, D. Monak, C. Q. Zhang, E. C. Butcher, and H. B. Greenberg. 2006. Redundant role of chemokines CCL25/TECK and CCL28/MEC in IgA+ plasmablast recruitment to the intestinal lamina propria after rotavirus infection. J. Immunol. 176: 5749-5759.
51. Castelletti, E., S. Lo Caputo, L. Kuhn, M. Borelli, J. Gajardo, M. Sinkala, D. Trabattoni, C. Kankasa, E. Lauri, A. Clivio, et al. 2007. The mucosaeassociated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS ONE 2: e969.
52. Berri, M., F. Meurens, F. Lefevre, C. Chevaleyre, G. Zanello, V. Gerdts, and H. Salmon. 2008. Molecular cloning and functional characterization of porcine CCL28: possible involvement in homing of IgA antibody secreting cells into the mammary gland. Mol. Immunol. 45: 271-277.
53. Kutzler, M. A., K. A. Kraynyak, S. J. Nagle, R. M. Parkinson, D. Zharikova, M. Chattergoon, H. Maguire, K. Muthumani, K. Ugen, and D. B. Weiner. 2010. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Ther. 17: 72-82.
54. Rainone, V., G. Dubois, V. Temchura, K. Überla, A. Clivio, M. Nebuloni, E. Lauri, D. Trabattoni, F. Veas, and M. Clerici. 2011. CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS ONE 6: e26979.
55. Hu, Q., K. B. Napier, J. O. Trent, Z. Wang, S. Taylor, G. E. Griffin, S. C. Peiper, and R. J. Shattock. 2005. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J. Mol. Biol. 350: 699-712.
56. Hu, Q. X., A. P. Barry, Z. X. Wang, S. M. Connolly, S. C. Peiper, and M. L. Greenberg. 2000. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74: 11858-11872.
57. Huang, X., W. Jin, K. Hu, S. Luo, T. Du, G. E. Griffin, R. J. Shattock, and Q. Hu. 2012. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. Virology 423: 97-106.
58. Du, T., K. Hu, J. Yang, J. Jin, C. Li, D. Stieh, G. E. Griffin, R. J. Shattock, and Q. Hu. 2012. Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination. Antimicrob. Agents Chemother. 56: 4640-4649.
59. Arias, M. A., A. Loxley, C. Eatmon, G. Van Roey, D. Fairhurst, M. Mitchnick, P. Dash, T. Cole, F. Wegmann, Q. Sattentau, and R. Shattock. 2011. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 29: 1258-1269.
60. Cranage, M. P., C. A. Fraser, A. Cope, P. F. McKay, M. S. Seaman, T. Cole, A. N. Mahmoud, J. Hall, E. Giles, G. Voss, et al. 2011. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 29: 1421-1430.
61. Wan, Y., L. Liu, L. Wu, X. Huang, L. Ma, and J. Xu. 2009. Deglycosylation or partial removal of HIV-1 CN54 gp140 V1/V2 domain enhances env-specific T cells. AIDS Res. Hum. Retroviruses 25: 607-617.
62. Hu, Q., X. Huang, and R. J. Shattock. 2010. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. J. Gen. Virol. 91: 2965-2973.
63. Sundling, C., M. N. E. Forsell, S. O'Dell, Y. Feng, B. Chakrabarti, S. S. Rao, K. Loré, J. R. Mascola, R. T. Wyatt, I. Douagi, and G. B. Karlsson Hedestam. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207: 2003-2017.
64. Montefiori, D. C. 2009. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485: 395-405.
65. Zhang, C., Y. Wan, J. Shi, M. Zhou, Z. Meng, S. Yuan, C. Qiu, X. Zhang, X. Xu, C. Liu, and J. Xu. 2010. Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade. AIDS Res. Hum. Retroviruses 26: 569-575.
66. Banerjee, K., P. J. Klasse, R. W. Sanders, F. Pereyra, E. Michael, M. Lu, B. D. Walker, and J. P. Moore. 2010. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 26: 445-458.
67. Clapham, P. R., and S. Lu. 2011. Vaccinology: precisely tuned antibodies nab HIV. Nature 477: 416-417.
68. Walker, B., and A. McMichael. 2012. The T-cell response to HIV. Cold Spring Harb. Perspect. Med. 2: 10.1101/cshperspect.a007054.
69. Virgin, H. W., and B. D. Walker. 2010. Immunology and the elusive AIDS vaccine. Nature 464: 224-231.
70. Wijesundara, D. K., R. J. Jackson, I. A. Ramshaw, and C. Ranasinghe. 2011. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol. Cell Biol. 89: 367-374.
71. Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32.
72. Van Roey, G. A., M. A. Arias, J. S. Tregoning, G. Rowe, and R. J. Shattock. 2012. Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice. Eur. J. Immunol. 42: 353-363.
73. Hinkula, J. 2007. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity. Expert Rev. Vaccines 6: 203-212.
74. Holmgren, J., and C. Czerkinsky. 2005. Mucosal immunity and vaccines. Nat. Med. 11(4, Suppl.)S45-S53.
75. Yan, Y. H., S. C. Qi, L. K. Su, Q. A. Xu, and M. W. Fan. 2013. Co-delivery of ccl19 gene enhances anti-caries DNA vaccine pCIA-P immunogenicity in mice by increasing dendritic cell migration to secondary lymphoid tissues. Acta Pharmacol. Sin. 34: 432-440.
76. Song, J. H., J. I. Kim, H. J. Kwon, D. H. Shim, N. Parajuli, N. Cuburu, C. Czerkinsky, and M. N. Kweon. 2009. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J. Immunol. 182: 6851-6860.
77. Cantrell, D. A., and K. A. Smith. 1984. The interleukin-2 T-cell system: a new cell growth model. Science 224: 1312-1316.
78. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240: 1169-1176.
79. Liao, W., J.-X. Lin, and W. J. Leonard. 2011. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23: 598-604.
80. Chun, S., M. Daheshia, S. Lee, S. K. Eo, and B. T. Rouse. 1999. Distribution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10. J. Immunol. 163: 2393-2402.
81. Chattergoon, M. A., T. M. Robinson, J. D. Boyer, and D. B. Weiner. 1998. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J. Immunol. 160: 5707-5718.